Country Access Report
Sweden maintains a restrictive narcotics framework: classical and novel psychedelics (psilocybin, MDMA, DMT, mescaline and most tryptamines) are controlled and have no routine medical/reimbursed use outside approved clinical research. Esketamine (Spravato) is authorised in the EU and has been the subject of Swedish health-economics assessment; access is limited to specialist psychiatry with supervised administration and regional/clinic-level funding decisions. Ketamine is an authorised anaesthetic and used in Swedish clinical research and some specialised/privately delivered off‑label psychiatric protocols, but routine outpatient ketamine infusion therapy for psychiatric indications is not a standard, nationally reimbursed service.
Read the access level as a starting point, then check the compound notes below. The practical question is whether a patient can move through a real pathway today, or whether access still depends on a trial, exception route, private-care model, or future reimbursement decision.
Look for approved use, named specialist settings, eligibility rules, and whether care is routine or exceptional.
Separate clinical trials, special access, compassionate use, and unlicensed-medicine routes from routine medical availability.
Check who pays, where care can happen, and whether trained teams, product supply, and site governance are in place.
These notes separate what is available today from research, exceptional-access, private-care, and payment routes. When the guide has not verified a pathway, the compound stays marked as incomplete rather than treated as unavailable.
Compound Access
Currently classified as a strictly controlled substance under Swedish narcotics law (included among substances/plant materials and mushrooms containing psilocybin/psilocin) with no authorised medical use outside approved clinical research. Access for therapeutic use requires specific approvals for clinical trials or special regulatory authorisations; recreational possession, cultivation (when prepared/dried) and distribution are criminalised. [1]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling with no authorised medical use outside approved clinical research. MDMA (ecstasy) is treated as a narcotic in Sweden; therapeutic use would require approved clinical trial pathways and regulatory clearance. Routine medical prescription or public reimbursement is not permitted. [1]
Compound Access
Esketamine (Spravato) is authorised in the European Union for adults with treatment‑resistant major depressive disorder as an adjunct to an oral antidepressant; the EMA marketing authorisation was granted on 18 December 2019. Access in Sweden is limited to specialist psychiatric settings where the product is administered under direct supervision because of safety (blood pressure elevation, dissociation) and risk‑management requirements. The Swedish Tandvårds- och läkemedelsförmånsverket (TLV) produced a health‑economic assessment to inform regional decision‑makers about Spravato for treatment‑resistant depression; regions (landsting/regioner) and specialist clinics determine local implementation, purchasing and whether/when the medicine is provided within publicly funded specialist services. As a centrally authorised medicine Spravato is legally available, but public reimbursement and availability have been handled via regional procurement and budget decisions rather than an automatic national, universal outpatient pharmacy subsidy. Clinical initiation typically requires a psychiatrist, monitoring before/after each administration, and facility capability for at‑least short observation. [1]. [2]
Compound Access
Ketamine is an authorised anaesthetic agent in Sweden and is legally used in standard anaesthesia, emergency medicine and pain medicine under usual medicinal product regulations. In psychiatry, low‑dose ketamine (intravenous or other routes) has been studied and implemented in specialist research settings and some clinical programmes for treatment‑resistant depression and acute suicidal ideation; those uses are generally off‑label (i.e., not an approved licensed psychiatric indication for racemic ketamine) and are managed at the institutional/clinic level. Swedish academic centres (for example Karolinska Institutet and regional psychiatric research groups) have run clinical trials of ketamine for depression, and individual treatment has been provided under study protocols or as clinician‑directed off‑label care where local governance and specialist oversight exist. Public reimbursement for off‑label ketamine psychiatric treatments is not established nationally; funding and availability are determined by region and treating clinic (many ketamine infusion programmes are privately delivered or financed locally). Safety and monitoring requirements (cardiovascular monitoring, observation after dosing) and the narcotics classification (ketamine is narcotic-classified in Sweden) mean access is restricted to controlled clinical settings. For Swedish context and reporting on clinical studies and debate about ketamine psychiatric use, see Swedish medical news and regulator commentary. [1].
Compound Access
Currently classified as a strictly controlled substance under Swedish drug scheduling and placed among substances regulated as narcotics/health‑hazardous tryptamines; there is no authorised medical use outside approved clinical research. Use or distribution (including in preparations such as ayahuasca that contain DMT) is prohibited except in approved research or specifically authorised import/compounding for a research protocol. [1]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling (listed/treated as a health‑hazardous or narcotic tryptamine in Swedish regulations) with no authorised medical use outside approved clinical research. Possession, sale or distribution is criminalised except within regulated research frameworks. [1]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws with no authorised medical use outside approved clinical research. There is no routine licenced or reimbursed pathway for ibogaine therapy in Sweden; any clinical research requires regulatory approvals. [1]
Compound Access
Because ayahuasca preparations contain DMT, they are treated under Sweden’s narcotics rules: currently classified such that sale, import and possession of ayahuasca (and other DMT‑containing preparations) are illegal except in approved research or tightly controlled authorisations. There is no authorised medical or reimbursed clinical use in routine Swedish healthcare. [1]
Compound Access
Currently classified as a strictly controlled substance under Swedish narcotics law (mescaline and mescaline‑containing cacti and preparations are regulated); there is no authorised medical/reimbursed use except within formally approved clinical research. Cultivation or preparation of mescaline‑containing cacti for use as a narcotic is covered by Swedish narcotics provisions. [1]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Substituted phenethylamines such as 2C‑series compounds are subject to control and criminal prohibition in Sweden; access is limited to sanctioned research. [1]
Last updated 2 Mar 2026. Source links come from the medical access guide.